These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 30857647)

  • 1. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
    Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
    Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
    Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
    Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
    Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
    BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
    Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
    J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
    Mathur VS; Li E; Wesson DE
    Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
    Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
    Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
    Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
    Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
    J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT.
    Witham MD; Band M; Chong H; Donnan PT; Hampson G; Hu MK; Littleford R; Lamb E; Kalra PA; Kennedy G; McNamee P; Plews D; Rauchhaus P; Soiza RL; Sumukadas D; Warwick G; Avenell A
    Health Technol Assess; 2020 Jun; 24(27):1-90. PubMed ID: 32568065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial.
    BiCARB study group
    BMC Med; 2020 Apr; 18(1):91. PubMed ID: 32268897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
    Agarwal R; Rossignol P; Romero A; Garza D; Mayo MR; Warren S; Ma J; White WB; Williams B
    Lancet; 2019 Oct; 394(10208):1540-1550. PubMed ID: 31533906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in management of chronic metabolic acidosis in chronic kidney disease.
    Chen W; Abramowitz MK
    Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.
    Witham MD; Band MM; Littleford RC; Avenell A; Soiza RL; McMurdo ME; Sumukadas D; Ogston SA; Lamb EJ; Hampson G; McNamee P;
    Trials; 2015 Aug; 16():326. PubMed ID: 26231610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Potential for Veverimer Drug-Drug Interactions.
    Parsell D; Shao J; Guttendorf R; Mathur V; Li E; Wu YS; Tsao L; Tabakman S; Stasiv Y; Lee A; Biyani K; Klaerner G
    Drug Metab Dispos; 2021 Jul; 49(7):490-500. PubMed ID: 34031138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.